Cargando…
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
Granulomatosis with polyangiitis and microscopic polyangiitis are small vessel vasculitides characterized by circulating antineutrophil circulating antibodies. Standard treatment for active severe disease has consisted of cyclophosphamide with glucocorticoids with or without plasmapheresis, which ac...
Autores principales: | Shah, Shivani, Geetha, Duvuru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918256/ https://www.ncbi.nlm.nih.gov/pubmed/27471722 http://dx.doi.org/10.2147/ITT.S55516 |
Ejemplares similares
-
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab
por: Geetha, Duvuru, et al.
Publicado: (2014) -
Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021) -
Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis
por: Harigai, Masayoshi, et al.
Publicado: (2019) -
Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020) -
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)